The ATR inhibition by Elimusertib enhances the radiosensitivity of MDA-MB-231 triple negative breast cancer in vitro

References

• Baschnagel AM, Elnaggar JH, VanBeek HJ, Kromke AC, Skiba JH, Kaushik S, Abel L, Clark PA, Longhurst CA, Nickel KP, et al. 2021. ATR inhibitor M6620 (VX-970) enhances the effect of radiation in non-small cell lung cancer brain metastasis patient-derived xenografts. Mol Cancer Ther. 20(11):2129–2139. doi:10.1158/1535-7163.MCT-21-0305
   PubMed Web of Science ®Google Scholar
• Blackford AN, Jackson SP. 2017. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell. 66(6):801–817. doi:10.1016/j.molcel.2017.05.015
   PubMed Web of Science ®Google Scholar
• Choi C, Park S, Cho WK, Choi DH. 2019. Cyclin D1 is associated with radiosensitivity of triple-negative breast cancer cells to proton beam irradiation. Int J Mol Sci. 20(19):4943. doi:10.3390/ijms20194943
   PubMed Web of Science ®Google Scholar
• Chughtai AA, Pannhausen J, Dinger P, Wirtz J, Knüchel R, Gaisa NT, Eble MJ, Rose M. 2022. Effective radiosensitization of bladder cancer cells by pharmacological ınhibition of DNA‐PK and ATR. Biomedicines. 10(6):1277. doi:10.3390/biomedicines10061277
   PubMed Web of Science ®Google Scholar
• Couch FB, Bansbach CE, Driscoll R, Luzwick JW, Glick GG, Bétous R, Carroll CM, Jung SY, Qin J, Cimprich KA, et al. 2013. ATR phosphorylates SMARCAL1 to prevent replication fork collapse. Genes Dev. 27(14):1610–1623. doi:10.1101/gad.214080.113
   PubMed Web of Science ®Google Scholar
• Faulhaber EM, Jost T, Symank J, Scheper J, Bürkel F, Fietkau R, Hecht M, Distel LV. 2021. Kinase inhibitors of dna-pk, atm and atr in combination with ionizing radiation can increase tumor cell death in hnscc cells while sparing normal tissue cells. Genes . 12(6):925. doi:10.3390/genes12060925
   PubMed Web of Science ®Google Scholar
• Goldstein M, Kastan MB. 2015. The DNA damage response: ımplications for tumor responses to radiation and chemotherapy. Annu Rev Med. 66(1):129–143. doi:10.1146/annurev-med-081313-121208
   PubMedGoogle Scholar
• Guney Eskiler G, Cecener G, Egeli U, Tunca B. 2018. Triple negative breast cancer: new therapeutic approaches and BRCA status. APMIS. 126(5):371–379. doi:10.1111/apm.12836
   PubMed Web of Science ®Google Scholar
• Haciefendi A, Eskiler GG. 2023. The suppression of ATR/Chk1 pathway by Elimusertib ATR inhibitor in triple negative breast cancer cells. Am J Transl Res. 15(7):4902–4911.
   Google Scholar
• Huang RX, Zhou PK. 2020. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Sig Transduct Target Ther. 5(1):60. doi:10.1038/s41392-020-0150-x
   Web of Science ®Google Scholar
• Ianevski A, Giri AK, Aittokallio T. 2022. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 50(W1):W739–W743. doi:10.1093/nar/gkac382
   PubMed Web of Science ®Google Scholar
• Italiano A. 2021. Atr inhibition as an attractive therapeutic resource against cancer. Cancer Discov. 11(1):14–16. doi:10.1158/2159-8290.CD-20-1354
   PubMed Web of Science ®Google Scholar
• Jin J, Tao Z, Cao J, Li T, Hu X. 2021. DNA damage response inhibitors: An avenue for TNBC treatment. Biochim Biophys Acta Rev Cancer. 1875(2):188521. doi:10.1016/j.bbcan.2021.188521
   PubMed Web of Science ®Google Scholar
• Lecona E, Fernandez-Capetillo O. 2018. Targeting ATR in cancer. Nat Rev Cancer. 18(9):586–595. doi:10.1038/s41568-018-0034-3
   PubMed Web of Science ®Google Scholar
• Liu C, Wang X, Qin W, Tu J, Li C, Zhao W, Ma L, Liu B, Qiu H, Yuan X. 2023. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer. Cancer Commun . 43(4):435–454. doi:10.1002/cac2.12412
   Web of Science ®Google Scholar
• Lohberger B, Glänzer D, Eck N, Stasny K, Falkner A, Leithner A, Georg D, Talebpoor M, Neshasteh-Riz A, K-SF, et al. 2022. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. Cancer Commun. 12(3):435–454. doi:10.1038/bjc.2012.265
   Google Scholar
• Mandapati A, Lukong KE. 2022. Triple negative breast cancer: approved treatment options and their mechanisms of action. J Cancer Res Clin Oncol. 149(7):3701–3719. doi:10.1007/s00432-022-04189-6
   PubMed Web of Science ®Google Scholar
• Roos WP, Kaina B. 2013. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 332(2):237–248. doi:10.1016/j.canlet.2012.01.007
   PubMed Web of Science ®Google Scholar
• De Ruysscher DKM, Belderbos JSA. 2012. Recent advances in radiotherapy for lung cancer. Lung Cancer Ther Annu. 7:128–137. doi:10.3109/9781841848679-13
   Google Scholar
• Sheng H, Huang Y, Xiao Y, Zhu Z, Shen M, Zhou P, Guo Z, Wang J, Wang H, Dai W, et al. 2020. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J Immunother Cancer. 8(1):e000340. doi:10.1136/jitc-2019-000340
   PubMed Web of Science ®Google Scholar
• Talebpoor M, Neshasteh-Riz A, Koo-Sha F, Eynali S. 2022. The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma. J Biomed Phys Eng. 12(3):267–276. doi:10.31661/jbpe.v0i0.1912-1000
   PubMedGoogle Scholar
• Tu X, Kahila MM, Zhou Q, Yu J, Kalari KR, Wang L, Harmsen WS, Yuan J, Boughey JC, Goetz MP, et al. 2018. ATR ınhibition ıs a promising radiosensitizing strategy for triple-negative Breast cancer. Mol Cancer Ther. 17(11):2462–2472. doi:10.1158/1535-7163.MCT-18-0470
   PubMed Web of Science ®Google Scholar
• Ward IM, Chen J. 2001. Histone H2AX ıs phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem. 276(51):47759–47762. doi:10.1074/jbc.C100569200
   PubMed Web of Science ®Google Scholar
• Wengner AM, Scholz A, Haendler B. 2020. Targeting DNA damage response in prostate and breast cancer. Int J Mol Sci. 21(21):8273. doi:10.3390/ijms21218273
   PubMed Web of Science ®Google Scholar
• Wengner AM, Siemeister G, Lücking U, Lefranc J, Wortmann L, Lienau P, Bader B, Bömer U, Moosmayer D, Eberspächer U, et al. 2020. The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage–inducing or repair–compromising therapies in preclinical cancer models. Mol Cancer Ther. 19(1):26–38. doi:10.1158/1535-7163.MCT-19-0019
   PubMed Web of Science ®Google Scholar
• Yang L, Liu Y, Sun C, Yang X, Yang Z, Ran J, Zhang Q, Zhang H, Wang X, Wang X. 2015. Inhibition of DNA-PKcs enhances radiosensitivity and increases the levels of ATM and ATR in NSCLC cells exposed to carbon ion irradiation. Oncol Lett. 10(5):2856–2864. doi:10.3892/ol.2015.3730
   PubMed Web of Science ®Google Scholar
• Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y, et al. 2021. First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) ınhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov. 11(1):80–91. doi:10.1158/2159-8290.CD-20-0868
   PubMed Web of Science ®Google Scholar
• Yin L, Duan JJ, Bian XW, Yu SC. 2020. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22(1):61. doi:10.1186/s13058-020-01296-5
   PubMed Web of Science ®Google Scholar